The stock of Inovio Pharmaceuticals Inc. (NASDAQ:INO) decreased by $0.0 on Tuesday to finish at $0.40, up 0.25 percent. The last five days have seen an average of 2,785,500 shares of common stock traded. 7 times new highs were reached in the current year, with a fall of -$1.1570. The average number of shares traded over the last 20 days was 2,302,155, while the average volume over the last 50 days totaled 2,619,450.
INO stock dropped -8.74% since last month. On 09/19/23, the company’s shares reached a one-month low of $0.3850. The stock touched a high of $2.61 on 01/13/23, after rallying from a low of $0.38 in 52 weeks. The price of INO stock has declined by -74.17% or -$1.1570 this year, reaching a new high 7 times. Still, the stock price is down -84.56% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
INO stock investors should be aware that Inovio Pharmaceuticals Inc. (INO) stock had its last reported insider trading activity 107 days ago on Jun 05. On Jun 05, Director Zoth Lota S. sold 5,700 shares at $0.56 each. This transaction resulted in the insider making $3,192. On Mar 13, Weiner David B. sold 5,833 shares at a price of US$1.15. After the transaction, the insider now owns 910,124 shares. Director Weiner David B. had earlier sold 11,668 shares on Feb 27 for $1.28 a share. The transaction was completed for $14,935.
Valuation Metrics
Beta for the stock is 0.98. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 12.17, the price-to-book (PB) ratio of 0.63.
Company paid $0.0690 per share in dividends, remained unchanged from $0.0690 last year.
Financial Health
For the three months ended June 29, Inovio Pharmaceuticals Inc.’s quick ratio was 3.90, while its current ratio was 3.90, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $277.84 million and revenue of $10.26 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. INO’s return on assets (ROA) during the last 12 months has been -54.30%. In the meantime, the return on equity (ROE) for the last 12 months was -78.60%.
Earnings Surprise
According to Inovio Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $2.39 million, while revenues rose by 31.38% to $2.32 million. It was predicted that Inovio Pharmaceuticals Inc.’s quarterly earnings would be -$0.13, but it ended up being -$0.14, beating the consensus by 7.10%. EBITDA was -$37.14 million for the quarter. At the end of Inovio Pharmaceuticals Inc.’s most recent quarter ended June 29, its liabilities totaled 63.67 million, while its total debt was $30.76 million. Equity owned by shareholders amounts to $268.07 million.
Technical Picture
Here’s a quick look at Inovio Pharmaceuticals Inc.’s (INO) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 34.03%, suggesting the stock is Neutral, with a 57.73% historical volatility rate.
The stochastic %K and %D were 18.27% and 26.05% respectively, while the average true range (ATR) was 0.0291. Based on the 14-day stochastic reading of 17.14%, the RSI (14) reading is 37.95%. On the 9-day MACD Oscillator, the stock is at -0.0287, and the 14-day reading is at -0.0354.
Analyst Ratings
Inovio Pharmaceuticals Inc. (NASDAQ: INO) was downgraded by Maxim Group to a a Hold rating in its latest research report. The stock was previously rated as a a Buy.
